Daxor Corporation announced the appointment of Lisa Quartley as its first SVP, Marketing and Commercial Development. Ms. Quartley will be leading a newly focused and reinvigorated commercialization effort for the company's unique diagnostic technology with the goal of making direct blood volume measurement a standard of care. Within the past five years she has led consultancy-side strategic efforts for key brands at Genentech, Novartis, Bristol-Myers Squibb, and Eisai.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.67 USD | +1.79% | +1.26% | +0.73% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.73% | 45.74M | |
+6.59% | 13.12B | |
+12.07% | 9.57B | |
+0.70% | 5.63B | |
+4.64% | 5.38B | |
+6.91% | 5.25B | |
+25.62% | 4.92B | |
+20.77% | 4.61B | |
+2.73% | 4.08B | |
+2.80% | 3.89B |
- Stock Market
- Equities
- DXR Stock
- News Daxor Corporation
- Daxor Corporation Appoints Lisa Quartley as its First SVP, Marketing and Commercial Development